MK-2010

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Advanced Solid TumorsMalignant NeoplamMalignant NeoplasmOvarian Cancer Recurrent

Phase 1

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

RecruitingNCT06843447

Merck Sharp & Dohme LLCOvarian Cancer Recurrent

Start: 2025-04-15End: 2031-02-07Target: 605Updated: 2026-09-11

Phase 2

A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

Not yet recruitingNCT07785609

Merck Sharp & Dohme LLCAdvanced Solid Tumors, Malignant Neoplasm

Start: 2026-09-30End: 2031-09-30Target: 200Updated: 2026-08-25

A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)

Not yet recruitingNCT07793942

Merck Sharp & Dohme LLCMalignant Neoplam, Advanced Solid Tumors

Start: 2026-09-29End: 2030-07-28Target: 480Updated: 2026-08-31